On March 01, 2022, shares of Exicure Inc. (XCUR) stock continued to rise in the after hours. The company reported no official announcement or SEC filing recently that can be attributed to the uptrend.
The stock remained bullish with a gain of 4.79% at a volume of 16.58 million shares in regular trading. Investors flocked towards the stock on Tuesday, as the day’s volume was 175% of its 65-day average. XCUR stock traded between $0.1970 and $0.2170 to close the session at a value of $0.2099 per share. Following the close of regular trading, the stock reached $0.2700 in the after-hours, continuing its bullish path. Hence, XCUR stock added a further 28.63% at an active after-hours volume of 8.56 million shares, on Tuesday.
The Spherical Nucleic Acid-based therapeutic developer, Exicure Inc. was founded in 2011. Currently, its 108.78 million outstanding shares trade at a market capitalization of $21.79 million.
What is Happening with XCUR?
Amid the Russian-Ukraine conflict, the stock nosedived to its 52-week low of $0.1360 on February 24 like most. The stock had since been in a mild uptrend. While the new low in the stock was reason enough for the stock rebound, the company also filed an SC 13D/A with the SEC on February 25. While gaining mildly for a number of days, the stock’s bullishness escalated in the after-hours on Tuesday. With no official reason, the stock seems to be gaining on external factors.
In the past five days, XCUR stock has added a good 22.61% while increasing by a mere 3.86% year to date. Moreover, the stock suffered a huge decline of 90.75% in the past year.
Leadership transition & Board Changes
On February 04, the company announced certain changes in its leadership and board of directors.
Resignations
The company’s then-President and CEO, Brian C. Bock submitted his resignation in order to pursue other opportunities. Upon his resignation, Mr. Bock will serve as a Special Advisor to the CEO during the transition period while remaining in an advisory role to the company.
Moreover, Timothy P. Walbert, Bosun Hau, and Ander Sassine also tendered their resignations from their positions at XCUR’s board.
Appointments
In addition, the company also announced the appointment of certain new members. Dr. Matthias Schroff was appointed as the President and CEO and replaced Mr. Bock on the board.
Furthermore, Dr. Elizabeth (Betsy) Garofalo was appointed as the Chair of the board and succeeded Mr. Walbert.
